Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS
30 Janvier 2024 - 2:00PM
Bionano Genomics, Inc. (BNGO) today announced the conclusion
of Bionano’s 2024 Symposium, the quintessential event for the
optical genome mapping (OGM) community, which was held January
22-25, 2024, and featured a record 32 oral presentations and 69
scientific posters from genomic scientists at leading institutions,
including Brigham and Women’s Hospital, The University of Texas MD
Anderson Cancer Center, Institute Curie, Memorial Sloan Kettering
Cancer Center and Johns Hopkins University School of Medicine.
Symposium had over 2,100 registrants from 92 countries and averaged
574 attendees per day. During this four-day online event,
presenters reported on their use of OGM for applications in cancer,
genetic disease, and cell and gene therapy.
Symposium 2024’s Defining Themes
Presentations delivered by researchers from across the
globe highlighted the following themes:
- OGM has moved beyond
concordance studies as data sets expand, research reveals
new, actionable biomarkers, and user groups form to drive
standardization and implementation of the workflow.
- Insights that OGM is providing
in hematological malignancy research are relevant in the context of
applications to potential therapeutic development and
maybe even one day patient management.
- OGM is helping to unravel
persistent, complex mysteries in genetic disease that
impact people, even in more common disorders like Down syndrome and
Marfan syndrome.
- OGM has the potential to meet
the key requirements of the cell and gene therapy
community.
- OGM can serve as an alternative
to, and an important bridge between, cytogenetics and molecular
pathology by elevating something that is digital and
molecular and complementing next-generation sequencing (NGS) which
is an essential component of molecular pathology today.
“We were impressed by the engagement at our 2024 Symposium and
are excited by the accomplishments of the global researchers who
presented their OGM data during sessions and in scientific
posters,” commented Alka Chaubey, PhD, FACMG, chief medical
officer at Bionano. “OGM’s ability to identify pathogenic variants
missed by many legacy techniques was highlighted in multiple
presentations, including a presentation from day three, covering a
research study that used OGM to successfully detect a repeat
expansion missed by conventional cytogenetic methods over 15 years
of analysis. Presenters also showcased OGM’s expansion into new
application areas, where it has potential to outperform classical
techniques, complement sequencing-based methods, and broaden
researchers’ understanding of genomic landscapes.”
Research shared over the four-day virtual event expanded
on key findings in several applications of OGM:
Day 1: New Standards in Hematologic
Malignancies
- OGM can provide researchers
with a simple, easy to implement workflow: Tiffany
Clouston from Saint John Regional Hospital highlighted increasing
demand for cytogenetics combined with limited staffing and training
resources as a driver for her lab’s adoption of OGM, with sample
preparation kits that are easy to use, and a sample-to-answer
workflow that delivers whole genome structural variant (SV)
analysis at high resolution, improving turnaround time.
- OGM can perform comparably to
classical cytogenetics and can enable detection of additional
pathogenic variants: Dr. Guilin Tang from the University
of Texas MD Anderson Cancer Center described results from a study
on 28 T-lymphoblastic leukemia (T-ALL) samples that showed that OGM
detected SVs in 100% of samples, even those with normal karyotype,
and revealed additional, clinically relevant information in 56% of
samples.
- International consortia have
formed all over the world and they are establishing guidelines for
standardized implementation of OGM and reporting of OGM
data: Agnes Daudignon from Lille Hospital and Dr. Adam
Smith from University of Toronto described two different consortia,
a French group of OGM users called FrOGG, and the International
Consortium for Hematologic Malignancies, which have formed to help
members validate, implement and standardize OGM, fueling its
expansion into new labs.
Day 2: New Frontiers in Oncology
- OGM has the potential to impact
therapy selection and cancer risk assessment and to expand the
understanding of heme malignancy applications compared to
sequencing and classical cytogenetic methods: Dr. Isabelle
Raymond-Bouchard from Maisonneuve-Rosemont Hospital presented
results from a study that used OGM to analyze 50 multiple myeloma
(MM) samples, showing that OGM was highly concordant with classical
cytogenetic methods and identified variants that led to a 30%
increase in prognostic information, which may result in improved
therapy selection. Dr. Scott Ryall from Brigham and Women’s
Hospital also highlighted OGM’s impact on MM research, with
findings that showed the workflow’s ability to detect clinically
relevant SVs and to expand the understanding of the structural
landscape of myeloma.
- OGM can identify clinically
relevant SVs missed by traditional methods: A study
presented by Dr. Miriam Bornhorst from Lurie Children’s
Hospital of Chicago showed that OGM was able to detect 20%
more pathogenic variants in 100 pediatric brain tumor samples than
classical cytogenetic methods.
- OGM can characterize and
stratify Homologous Recombination Deficiency (HRD)
in breast tumor samples: In a research study on
Triple-Negative Breast Cancer (TNBC) presented by Dr. Marc-Henri
Stern from Institute Curie, OGM was able to clearly differentiate
between homologous recombination proficient (HRP) and deficient
(HRD) breast cancer cells, which could potentially help patients
get access to life saving PARP inhibitors.
- High performance and utility
make OGM a potential key assay for cancer research:
Presenters shared data that underscored OGM’s high sensitivity,
specificity, and fast turnaround time when compared to classical
techniques including karyotyping (KT) and fluorescence in situ
hybridization (FISH), which have been the standard for cytogenetic
analysis of cancer samples for decades.
Day 3: Advances in Constitutional
Applications
- OGM detected significant SVs
missed by NGS, long read sequencing (LRS) and classical cytogenetic
methods: Presentations delivered by Dr. Nikhil Sahajpal
from Greenwood Genetic Center, Dr. Laila El Khattabi from AP-HP
Sorbonne, and Dr. Maria Clara Bonaglia from Scientific Institute E.
Medea included findings from OGM that were missed by multiple other
methods and that proved important in research connected to
unraveling longstanding mysteries in genetic disease.
- OGM can be highly concordant
with traditional methods and accomplish, in a single assay, what
took multiple assays in 60% of samples or more: In pre-
and postnatal constitutional genetic disorder studies presented by
Dr. Roger Stevenson from Greenwood Genetic Center, OGM was shown to
be a complete replacement for multiple techniques used in classical
cytogenetics.
- Combination of OGM and NGS can
improve upon and potentially replace traditional
workflows: Across the presentations in day 3, the
combination of OGM and NGS was shown to be highly complementary and
that it may enable comprehensive genomic variation analysis in
constitutional genetic diseases.
Day 4: OGM in Cell and Gene Therapy
- OGM is the only genome-wide
tool used by the National Institute of Standards and Technology
(NIST) genome editing consortium: In the search for
potentially deleterious effects of gene editing, OGM is the only
genome-wide tool that meets the NIST genome editing consortium
requirements for cost, accuracy, performance and speed. All other
technologies that are part of the NIST consortium are targeted
assays.
- OGM can offer high resolution
and sensitivity compared to classical cytogenetic methods:
OGM was reported to reliably detect on-target effects of
CRISPR/Cas9 gene editing at variant allele frequency (VAF) as low
as 1%, potentially providing an advantage over other techniques in
quality control of pluripotent stem cells and evaluation of the
integrity of laboratory cell lines.
- OGM can outperform classical
cytogenetic methods to screen cell lines more easily for genomic
instability and off-target events: Owen Pearce from
eGenesis shared data that highlighted how OGM can offer
improvements in quality control compared to methods like KT, which
will be crucial to cell and gene therapy applications with
increasing pressure from the FDA.
“Symposium 2024 underscored OGM’s utility and demonstrated that
the workflow has expanded beyond concordance studies. The event
presentations provided data that showed OGM’s expansion into new
applications, and its ability to uncover new actionable biomarkers.
We were pleased to see researchers share findings that showed that
OGM has the potential to impact genome research in a meaningful
way,” commented Erik Holmlin, PhD, president and chief
executive officer at Bionano. “I would encourage anyone who was
unable to attend live to login, view these presentations and see
how bright the future of cytogenetics is with OGM.”
Poster winners:
Award |
Title |
Author |
Institution |
Grand prize winner |
Comprehensive Analysis of B-Cell Precursor Acute Lymphoblastic
Leukemia: Insights from Optical Genome Mapping and Next-Generation
Sequencing |
Danielle Brandes |
University Hospital Düsseldorf |
Oncology |
Complex Karyotypes and Novel Findings Revealed by Optical Genome
Mapping in Hematologic Malignancies |
Dr. Shivaprasad H. Sathyanarayana |
Dartmouth Health |
Constitutional Applications |
Optical Genome Mapping Help in Analyzing the Products of Conception
Cases in High Maternal Cell Contamination: A Preliminary Study |
Kolhe Laboratory |
Augusta University |
Research and Discovery |
A Search for Genetic Determinants in Neural Tube Defects Using
Optical Genome Mapping |
Dr. Nikhil Sahajpal |
Greenwood Genetic Center |
On-demand presentations are available here with free
registration.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “can,” “could,” “may,” “potential,” “will” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, OGM’s utility for research in areas including
cancer, genetic disease, and cell and gene therapy; the ability and
utility of OGM to reveal new, actionable biomarkers; the ability
and utility of OGM to identify SVs in hematological malignancy
research that are relevant in the context of applications to
potential therapeutic development and maybe even one day patient
management; the ability and utility of OGM to help unravel
persistent, complex mysteries in genetic disease disorders like
Down syndrome and Marfan syndrome; the ability and utility of OGM
to meet the key requirements of the cell and gene therapy
community; the ability and utility of OGM to serve as an important
bridge between cytogenetics and molecular pathology by elevating
something that is digital and molecular and complementing NGS; the
ability and utility of OGM to uncover new actionable biomarkers;
the ability and utility of OGM to identify SVs highly concordant
with classical cytogenetic methods; the ability and utility of OGM
to identify SVs that were missed by classical cytogenetic methods;
the ability and utility of OGM to provide results similar to
results similar to the presentations given and the posters made
available during our 2024 Symposium; the growth and adoption of
OGM; and the ability of OGM to replace or complement traditional
cytogenetic analysis tools and methods. Each of these
forward-looking statements involves risks and uncertainties. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include the risks and uncertainties
associated with: the impact of geopolitical and macroeconomic
developments, such as recent and future bank failures, global
pandemics, inflation, supply chain disruptions, the ongoing
conflicts between Ukraine and –Russia and Israel and Hamas, on our
business and the global economy; the failure of OGM to be useful
for research in areas including cancer, genetic disease, and cell
and gene therapy; the failure of OGM to reveal new, actionable
biomarkers; the failure of OGM to identify SVs in hematological
malignancy research that are relevant in the context of
applications to potential therapeutic development and maybe even
one day patient management; the failure of OGM to help unravel
persistent, complex mysteries in genetic disease disorders like
Down syndrome and Marfan syndrome; the failure of OGM to meet the
key requirements of the cell and gene therapy community; the
failure of OGM to serve as an important bridge between cytogenetics
and molecular pathology by elevating something that is digital and
molecular and complementing NGS; the failure of OGM to uncover new
actionable biomarkers; the failure of OGM to identify SVs highly
concordant with classical cytogenetic methods; the failure of OGM
to identify SVs that were missed by classical cytogenetic methods;
the failure of OGM to provide results similar to results similar to
the presentations given and the posters made available during our
2024 Symposium; future study results contradicting the results
reported in the presentations given and the posters made available
at our 2024 Symposium; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; changes in
our strategic and commercial plans; our ability to obtain
sufficient financing to fund our strategic plans and
commercialization efforts and our ability to continue as a “going
concern”; the ability of medical and research institutions to
obtain funding to support adoption or continued use of our
technologies; and the risks and uncertainties associated with our
business and financial condition in general, including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2022 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bionano Genomics (NASDAQ:BNGO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024